Hélène Lasolle1,2, Christine Cortet3, Fréderic Castinetti4, Lucie Cloix5, Philippe Caron6, Brigitte Delemer7, Rachel Desailloud8, Christel Jublanc9, Christine Lebrun-Frenay10, Jean-Louis Sadoul11, Luc Taillandier12, Marie Batisse-Lignier13, Fabrice Bonnet14, Nathalie Bourcigaux15, Damien Bresson16, Olivier Chabre17, Philippe Chanson18,19, Cyril Garcia20, Magalie Haissaguerre21, Yves Reznik22, Sophie Borot23, Chiara Villa24,25, Alexandre Vasiljevic26, Stephan Gaillard27, Emmanuel Jouanneau2,28, Guillaume Assié29, Gérald Raverot1,2. 1. Fédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Bron, France. 2. Université Lyon 1Lyon, France. 3. Service d'EndocrinologieHôpital Claude Huriez, CHRU de Lille, Lille, France. 4. Service d'EndocrinologieHôpital de La Timone, CHU de Marseille, Marseille, France. 5. Service d'EndocrinologieHôpital Bretonneau, CHRU de Tours, Tours, France. 6. Service d'EndocrinologieHôpital Larrey, CHU de Toulouse, Toulouse, France. 7. Service d'EndocrinologieHôpital Robert Debré, CHU de Reims, Reims, France. 8. Service d'EndocrinologieHôpital Nord, CHU d'Amiens-Picardie, Amiens, France. 9. Service d'EndocrinologieHôpital de La Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France. 10. Service de NeurologieUnité de Neuro-oncologie, Hôpital Pasteur 2, CHU de Nice, Nice, France. 11. Service d'EndocrinologieHôpital L'Archet, CHU de Nice, Nice, France. 12. Service de NeurologieCHU de Poitiers, Poitiers, France. 13. Service d'EndocrinologieHôpital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France. 14. Service d'EndocrinologieCHU de Rennes, Rennes, France. 15. Service d'EndocrinologieHôpital Saint Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France. 16. Service de NeurochirurgieHôpital Lariboisière, Assistance Publique des Hôpitaux de Paris, Paris, France. 17. Service d'EndocrinologieCHU de Grenoble-Alpes, La Tronche, France. 18. Service d'Endocrinologie et des Maladies de la ReproductionHôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France. 19. INSERM 1185Fac Med Paris Sud, Univ Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France. 20. Service d'EndocrinologieHôpital d'Instruction des Armées Bégin, Saint-Mandé, France. 21. Service d'EndocrinologieHôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France. 22. Service d'EndocrinologieCHU de Caen, Caen, France. 23. Service d'EndocrinologieHôpital Jean Minjoz, CHU de Besançon, Besançon, France. 24. Service d'Anatomie et Cytologie PathologiquesHôpital Foch, Suresnes, France. 25. INSERM U1016 CNRS UMR 8104Paris, France. 26. Centre de Pathologie EstGroupement Hospitalier Est, Hospices Civils de Lyon, Bron, France. 27. Service de NeurochirurgieHôpital Foch, Suresnes, France. 28. Service de NeurochirurgieHôpital Neurologique, Hospices Civils de Lyon, Bron, France. 29. Department of EndocrinologyInstitut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Abstract
OBJECTIVES: Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival. DESIGN: Multicenter retrospective study by members of the French Society of Endocrinology. METHODS: Forty-three patients (14 women) treated with TMZ between 2006 and 2016 were included. Most tumors were corticotroph (n = 23) or lactotroph (n = 13), and 14 were carcinomas. Clinical/pathological characteristics of PT, as well as data from treatment evaluation and from the last follow-up were recorded. A partial response was considered as a decrease in the maximal tumor diameter by more than 30% and/or in the hormonal rate by more than 50% at the end of treatment. RESULTS: The median treatment duration was 6.5 cycles (range 2-24), using a standard regimen for most and combined radiotherapy for six. Twenty-two patients (51.2%) were considered as responders. Silent tumor at diagnosis was associated with a poor response. The median follow-up after the end of treatment was 16 months (0-72). Overall survival was significantly higher among responders (P = 0.002); however, ten patients relapsed 5 months (0-57) after the end of TMZ treatment, five in whom TMZ was reinitiated without success. DISCUSSION: Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols.
OBJECTIVES: Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival. DESIGN: Multicenter retrospective study by members of the French Society of Endocrinology. METHODS: Forty-three patients (14 women) treated with TMZ between 2006 and 2016 were included. Most tumors were corticotroph (n = 23) or lactotroph (n = 13), and 14 were carcinomas. Clinical/pathological characteristics of PT, as well as data from treatment evaluation and from the last follow-up were recorded. A partial response was considered as a decrease in the maximal tumor diameter by more than 30% and/or in the hormonal rate by more than 50% at the end of treatment. RESULTS: The median treatment duration was 6.5 cycles (range 2-24), using a standard regimen for most and combined radiotherapy for six. Twenty-two patients (51.2%) were considered as responders. Silent tumor at diagnosis was associated with a poor response. The median follow-up after the end of treatment was 16 months (0-72). Overall survival was significantly higher among responders (P = 0.002); however, ten patients relapsed 5 months (0-57) after the end of TMZ treatment, five in whom TMZ was reinitiated without success. DISCUSSION: Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols.
Authors: Odelia Cooper; Vivien S Bonert; Jeremy Rudnick; Barry D Pressman; Janet Lo; Roberto Salvatori; Kevin C J Yuen; Maria Fleseriu; Shlomo Melmed Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958
Authors: D Bengtsson; H D Schrøder; K Berinder; D Maiter; C Hoybye; O Ragnarsson; U Feldt-Rasmussen; Å Krogh Rasmussen; A van der Lely; M Petersson; G Johannsson; M Andersen; P Burman Journal: Endocrine Date: 2018-09-24 Impact factor: 3.633
Authors: Yu Mei; Wenya Linda Bi; James Agolia; Changchen Hu; Alexandra M Giantini Larsen; David M Meredith; Sally Al Abdulmohsen; Tejus Bale; Gavin P Dunn; Malak Abedalthagafi; Ian F Dunn Journal: Pituitary Date: 2021-01-25 Impact factor: 4.107
Authors: Andrew L Lin; Mark T A Donoghue; Sharon L Wardlaw; T Jonathan Yang; Lisa Bodei; Viviane Tabar; Eliza B Geer Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958